Barnasconi C, Salmon D, Matheron S, Mazeron MC, Cassoux I, Le Hoang P, Durand-Zaleski I, Costagliola D; International Conference on AIDS.
Int Conf AIDS. 2000 Jul 9-14; 13: abstract no. TuPeB3130.
C. Barnasconi, Inserm SC4, Faculte de Medecine de Saint Antoine, 27 Rue de Chaligny, 75571 Paris Cedex 12, France, Tel.: +331 400 114 63, Fax: +331430 739 57, E-mail: bernasco@b3e.jussieu.fr
Background: In France where more than 88% of HIV infected patients are treated with HAART, the incidence of CMV disease has sharply decreased and once can hypothetise that the natural history has not remained unchanged. Objectives: to describe clinical, immunological, virological characteristics and evolution of recent episodes of CMV disease. Methods: multicenter, prospective survey of all CMV disease episodes occurring in HIV infected patients over a one year period. Results: Only 22 patients were included in 13 centers between December 1998 and August 1999. Since then 14 patients were included and their follow-up data are not yet available. Among the first 22 patients, 8 presented with recurrence, 13 with first episode and one with primary infection. Sex ratio was 4.5 and median age 38. AIDS History was present in 20 patients. median CD4 count was 27/mm3 (range: 0-492) (9/mm3 for patients with first episode and 44 for those with recurrence) and 4 had more than 100/mm3 . Median HIV viral load (VL) was 261000 cp/ml (range: >200-1 437 33). 18 patients were under ARV bi/tritherapy with VL between 12000-1107200 cp/ml in 16 and L 504 in only two, 4 patients were not treated.. The 8 recurrences were retinitis with a median time since previous episode of 8 months (range: 3-10). For patients with no previous CMV disease (n = 14), CMV localisations were retinitis (5), colitis or gastritis (5), optic nevritis (1), systemic disease (2), primoinfection (1). During a mean follow-up of 3.5 months, 6 patients had a recurrence. The rate of recurrences was estimated by KM as 27% at 3 months (95% CI 4%, 50%). Conclusion: This survey shows that CMV disease: (1) is still very rare, (2) occurs mainly in case of ARV treatement failure and in profoundly immunosuppressed patients. The median time between two episodes is markedly increased.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- France
- HIV
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- Humans
- Incidence
- Longitudinal Studies
Other ID:
UI: 102239040
From Meeting Abstracts